Association between PET-based TheraP eligibility and ¹⁷⁷Lu-PSMA-617 (LuPSMA) outcomes in VISION-eligible patients with metastatic castration-resistant prostate cancer (mCRPC).

Authors

Ridvan Arda Demirci

University of Washington, Seattle, WA

Ridvan Arda Demirci , Roman Gulati , Alireza Ghodsi , Peter Nelson , Heather H. Cheng , Jessica E. Hawley , Todd Yezefski , Michael C. Haffner , Robert Bruce Montgomery , Michael Thomas Schweizer , Evan Y. Yu , Delphine L Chen , Amir Iravani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Diagnostics and Imaging

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 41)

DOI

10.1200/JCO.2024.42.4_suppl.41

Abstract #

Poster Bd #

A20

Abstract Disclosures

FEATURED

Association between PET-based TheraP eligibility and ¹⁷⁷Lu-PSMA-617 (LuPSMA) outcomes in VISION-eligible patients with metastatic castration-resistant prostate cancer (mCRPC).

Authors

Ridvan Arda Demirci

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.